IL313553A - Fusion proteins containing alpha-L-iduronidase enzymes and methods - Google Patents

Fusion proteins containing alpha-L-iduronidase enzymes and methods

Info

Publication number
IL313553A
IL313553A IL313553A IL31355324A IL313553A IL 313553 A IL313553 A IL 313553A IL 313553 A IL313553 A IL 313553A IL 31355324 A IL31355324 A IL 31355324A IL 313553 A IL313553 A IL 313553A
Authority
IL
Israel
Prior art keywords
iduronidase
enzymes
alpha
methods
fusion proteins
Prior art date
Application number
IL313553A
Other languages
English (en)
Hebrew (he)
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of IL313553A publication Critical patent/IL313553A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL313553A 2021-12-17 2022-12-16 Fusion proteins containing alpha-L-iduronidase enzymes and methods IL313553A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163291283P 2021-12-17 2021-12-17
PCT/US2022/053196 WO2023114485A1 (en) 2021-12-17 2022-12-16 Fusion proteins comprising alpha-l-iduronidase enzymes and methods

Publications (1)

Publication Number Publication Date
IL313553A true IL313553A (en) 2024-08-01

Family

ID=85175822

Family Applications (1)

Application Number Title Priority Date Filing Date
IL313553A IL313553A (en) 2021-12-17 2022-12-16 Fusion proteins containing alpha-L-iduronidase enzymes and methods

Country Status (12)

Country Link
US (1) US20250136963A1 (https=)
EP (1) EP4448746A1 (https=)
JP (1) JP2024546129A (https=)
KR (1) KR20240119118A (https=)
CN (1) CN118401660A (https=)
AR (1) AR128003A1 (https=)
AU (1) AU2022415476A1 (https=)
CA (1) CA3241240A1 (https=)
IL (1) IL313553A (https=)
MX (1) MX2024007319A (https=)
TW (1) TW202340459A (https=)
WO (1) WO2023114485A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202542190A (zh) * 2023-12-20 2025-11-01 美商戴納立製藥公司 包含酸性α—葡萄糖苷酶之融合蛋白及其方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3218000A2 (en) * 2014-11-10 2017-09-20 Alexion Pharmaceuticals, Inc. Therapeutic compositions of alpha-l-iduronidase, iduronate-2-sulfatase, and alpha-galactosidase a and methods of use thereof
TWI769982B (zh) * 2015-06-24 2022-07-11 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之抗人類運鐵蛋白受體抗體
WO2018152285A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Transferrin receptor transgenic models
AU2018345303B2 (en) 2017-10-02 2025-09-18 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
CA3101202A1 (en) * 2018-06-18 2019-12-26 Denali Therapeutics Inc. Fusion proteins comprising progranulin
EP4100419A4 (en) * 2020-02-07 2024-05-29 Denali Therapeutics Inc. METHODS OF TREATING HUNTER SYNDROME

Also Published As

Publication number Publication date
WO2023114485A1 (en) 2023-06-22
AU2022415476A1 (en) 2024-07-04
JP2024546129A (ja) 2024-12-17
KR20240119118A (ko) 2024-08-06
CN118401660A (zh) 2024-07-26
MX2024007319A (es) 2024-07-22
CA3241240A1 (en) 2023-06-22
US20250136963A1 (en) 2025-05-01
EP4448746A1 (en) 2024-10-23
AR128003A1 (es) 2024-03-20
TW202340459A (zh) 2023-10-16

Similar Documents

Publication Publication Date Title
LT4232463T (lt) Interleukino-2-fc susiliejimo baltymai ir panaudojimo būdai
AU2021365129A9 (en) Interleukin-2-fc fusion proteins and methods of use
IL288373A (en) flt3l-fc fusion proteins and methods of use
EP4194556A4 (en) FUSION PROTEIN AND USE THEREOF
SI4073098T1 (sl) Ultra dolgo delujoči inzulin-fc fuzijski proteini in postopki uporabe
IL306074A (en) UPAR antibodies and fusion proteins with them
IL319851A (en) LRRC-15 binding protein structures and uses thereof
EP3930767A4 (en) ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-TM4SF1 ANTIBODIES AND METHODS OF USE THEREOF
MA71661A (fr) Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées
IL313553A (en) Fusion proteins containing alpha-L-iduronidase enzymes and methods
IL304233A (en) Sialidase-antibody-her2 fusion proteins and methods of using them
EP4186517A4 (en) FUSION PROTEIN COMPRISING PD-L1 PROTEIN AND USE THEREOF
IL318711A (en) Immune modulator proteins and related methods
GB2624541B (en) Multivalent proteins and screening methods
HK40118007A (en) Fusion proteins comprising alpha-l-iduronidase enzymes and methods
EP3994180A4 (en) ANTIBODY-HER2-SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF
IL326224A (en) Antibody conjugates and fusion proteins
EP4423260A4 (en) Truncated and fusion proteins
IL304228A (en) Sialidase-antibody-pd-1 fusion proteins and methods of using them
EP4107190A4 (en) FUSION PROTEINS AND USES THEREOF
PL4122447T3 (pl) Preparat białka fuzyjnego zawierający białka il-2 i cd80
IL305817A (en) Systems and methods for protein expression
HK40098269A (en) Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
IL299757A (en) SARS-COV-2 proteins, antibodies against SARS-COV-2, and methods of using them
EP4509136A4 (en) FUSION PROTEIN AND ITS USE